Resource table {#s0005}
==============

Name of stem cell lineKCL039InstitutionKing\'s College London, London UKDerivation teamNeli Kadeva, Victoria Wood, Glenda Cornwell, Stefano Codognotto, Emma StephensonContact person and emailDusko Ilic, email: dusko.ilic\@kcl.ac.ukDate archived/stock dateFeb. 03, 2012Type of resourceBiological reagent: cell lineSub-typeHuman pluripotent stem cell lineOriginHuman embryoKey marker expressionPluripotent stem cell markers: NANOG, OCT4, TRA-1-60, TRA-1-81, alkaline phosphatase (AP) activityAuthenticationIdentity and purity of line confirmedLink to related literature (direct URL links and full references)1)Jacquet, L., Stephenson, E., Collins, R., Patel, H., Trussler, J., Al-Bedaery, R., Renwick, P., Ogilvie, C., Vaughan, R., Ilic, D., 2013. Strategy for the creation of clinical grade hESC line banks that HLA-match a target population. EMBO Mol. Med. 5 (1), 10--17.doi: 10.1002/emmm.201201973\
<http://www.ncbi.nlm.nih.gov/pubmed/23161805>\
2)Canham, A., Van Deusen, A., Brison, D.R., De Sousa, P., Downie, J., Devito, L., Hewitt, Z.A., Ilic, D., Kimber, S.J., Moore, H.D., Murray, H., Kunath, T., 2015. The molecular karyotype of 25 clinical-grade human embryonic stem cells lines. *Sci. Rep.* 5, 17258.doi: 10.1038/srep17258 <http://www.ncbi.nlm.nih.gov/pubmed/26607962>\
3)Ilic, D., Stephenson, E., Wood, V., Jacquet, L., Stevenson, D., Petrova, A., Kadeva, N., Codognotto, S., Patel, H., Semple, M., Cornwell, G., Ogilvie, C., Braude, P., 2012. Derivation and feeder-free propagation of human embryonic stem cells under xeno-free conditions. Cytotherapy. 14 (1), 122--128.doi: 10.3109/14653249.2011.623692\
<http://www.ncbi.nlm.nih.gov/pubmed/22029654>\
4)Stephenson, E., Jacquet, L., Miere, C., Wood, V., Kadeva, N., Cornwell, G., Codognotto, S., Dajani, Y., Braude, P., Ilic, D., 2012. Derivation and propagation of human embryonic stem cell lines from frozen embryos in an animal product-free environment. Nat. Protoc. 7 (7), 1366--1381.doi: 10.1038/nprot.2012.080\
<http://www.ncbi.nlm.nih.gov/pubmed/22722371>Information in public databasesKCL039 is a National Institutes of Health (NIH) registered hESC line\
NIH Registration Number: NIHhESC-14-0274\
<http://grants.nih.gov/stem_cells/registry/current.htm?id=680>EthicsThe hESC line KCL039 is derived under license from the UK Human Fertilisation and Embryology Authority (research license numbers: R0075 and R0133) and also has local ethical approval (UK National Health Service Research Ethics Committee Reference: 06/Q0702/90).\
Informed consent was obtained from all subjects and the experiments conformed to the principles set out in the WMA Declaration of Helsinki and the NIH Belmont Report. No financial inducements are offered for donation.

Resource details {#s0010}
================

Consent signedNov. 15, 2011Embryo thawedJan. 16, 2012UK Stem Cell Bank Deposit ApprovalReference: SCSC12-37SexMale 46, XYGradeClinicalDisease statusHealthy/UnaffectedKaryotype (aCGH)No copy number changes detectedSNP arrayNo structural genomic variants detected ([@bb0005])DNA fingerprintAllele sizes (in bp) of 16 microsatellite markers specific for chromosomes 13, 18 and 21 ([@bb0025])HLA typingHLA-A 01, 24; B 35, 49; Bw 4, 6; C 04, 07; DRB1 03; DRB3 01/02; DQB1 02 ([@bb0025], [@bb0005])Viability testingPassMycoplasmaNegativeSterilityPassPluripotent markers\
(immunostaining)\
([Fig. 1](#f0005){ref-type="fig"})NANOG, OCT4, TRA-1-60, TRA-1-81, AP activityThree germ layers differentiation in vitro\
(immunostaining)\
([Fig. 2](#f0010){ref-type="fig"})Endoderm: AFP\
Ectoderm: TUBB3 (tubulin, beta 3 class III)\
Mesoderm: ACTA2 (actin, alpha 2, smooth muscle)Sibling lines availableNo

We generated a KCL039 clinical grade hESC line following protocols, established previously ([@bb0020], [@bb0035]), and now adapted to cGMP conditions. The expression of the pluripotency markers was tested after a freeze/thaw cycle ([Fig. 1](#f0005){ref-type="fig"}). Differentiation potential into three germ layers was verified in vitro ([Fig. 2](#f0010){ref-type="fig"}).

The embryo donors were negative for Human Immunodeficiency Virus 1/2 (HIV1/2), Hepatitis B (HepB, HCB) and C Virus (HepC, HCV). We did not retest the line.

We also generated a research grade of the KCL039 line that is adapted to feeder-free conditions.

Materials and methods {#s0015}
=====================

Consenting process {#s0020}
------------------

We distributed patient information sheets (PIS) and consent forms to the in vitro fertilization (IVF) patients if they opted to donate to research embryos that were stored for 5 or 10 years. They mail signed consent back to us and that might be months after the PIS and consent forms were mailed to them. If in the meantime new versions of PIS/consent forms are implemented, we do not send these to the patients or ask them to re-sign; the whole process is done with the version that was given them initially. The PIS/consent documents (FRO-V.10) were created on Sep. 19, 2011. The HFEA Code of Practice that was in effect at the time of document creation was: Edition 8 --- R.3 (<http://www.hfea.gov.uk/2999.html>). The donor couple signed the consent on Nov. 15, 2011. The HFEA Code of Practice that was in effect at the time of donor signature was: Edition 8 --- R.4. The HFEA Code of Practice Edition 8 --- R.3 was in effect from Apr. 07, 2011 to Oct. 01, 2011, whereas 8 --- R.4 was in effect from Oct. 02, 2011 to Apr. 02, 2012.

Embryo culture and micromanipulation {#s0025}
------------------------------------

Embryo culture and laser-assisted dissection of inner cell mass (ICM) were carried out as previously described in details ([@bb0020], [@bb0035]). The cellular area containing the ICM was then washed and transferred to plates containing mitotically inactivated human neonatal foreskin fibroblasts (HFF).

Cell culture {#s0030}
------------

ICM plated on mitotically inactivated HFF were cultured as previously described ([@bb0020], [@bb0035]). Trophectoderm cells were removed mechanically from outgrowth ([@bb0010], [@bb0015]). hESC colonies were expanded and cryopreserved at the third passage.

Viability test {#s0035}
--------------

Straws with the earliest frozen passage (p. 2--3) are thawed and new colonies are counted three days later. These colonies are then expanded up to passage 8, at which point cells were partly frozen and partly subjected to a standard battery of tests (pluripotency markers, in vitro and in vivo differentiation capability, genetics, sterility, and mycoplasma).

Pluripotency {#s0040}
------------

Pluripotency in vitro was assessed using two different techniques: enzymatic activity assay \[alkaline phosphatase (AP) assay\] and immunostaining as previously described ([@bb0020], [@bb0035]).

Differentiation {#s0045}
---------------

Spontaneous differentiation into three germ layers was assessed in vitro as previously described ([@bb0030], [@bb0035]).

Genotyping {#s0050}
----------

DNA was extracted from hESC cultures using a Chemagen DNA extraction robot according to the manufacturer\'s instructions. Amplification of polymorphic microsatellite markers was carried out as previously described ([@bb0020]). Allele sizes were recorded to give a unique fingerprint of each cell line.

Array comparative genomic hybridization (aCGH) {#s0055}
----------------------------------------------

aCGH was performed as described in detail by [@bb0020].

Whole-genome single nucleotide polymorphism (SNP) array {#s0060}
-------------------------------------------------------

SNP array was performed as described in detail by [@bb0005].

HLA typing {#s0065}
----------

HLA-A, -B and -DRB1 typing was performed with a PCR sequence-specific oligonucleotide probe (SSOP; Luminex, Austin, TX, USA) hybridization protocol at the certified Clinical Transplantation Laboratory, Guy\'s and St Thomas\' NHS Foundation Trust and Serco Plc. (GSTS) Pathology (Guy\'s Hospital, London, UK) as previously described ([@bb0025]). HLA typing was also performed independently by another group ([@bb0005]).
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![Expression of pluripotency markers. Pluripotency is confirmed by immunostaining (Oct4, Nanog, TRA-1-60, TRA-1-81) and alkaline phosphatase (AP) activity assay. Actin stress fibers, visualized with rhodamine-phalloidin (red), are present in both feeders and hES cell colonies, whereas AP activity (green) is detected only in hES cells. Scale bar, 50 μm.](gr1){#f0005}

![Differentiation of three germ layers in vitro is confirmed by detection of markers: smooth muscle actin (red) for mesoderm, β-III tubulin (red) for ectoderm and α-fetoprotein (red) for endoderm. Nuclei are visualized with Hoechst 33342 (blue). Scale bar, 50 μm.](gr2){#f0010}
